Trial Profile
Enhanced efficacy of photodynamic therapy in combination with 3,75% imiquimod - a randomised, prospective , observer-blinded study in patients with actinic keratosis
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 27 Oct 2022
Price :
$35
*
At a glance
- Drugs Aminolevulinic acid (Primary) ; Imiquimod (Primary)
- Indications Actinic keratosis
- Focus Therapeutic Use
- Acronyms PDT vs PDT in combination with 3,75% Imiquimod in patients with actinic keratosis
- 27 Oct 2022 Status changed from recruiting to discontinued.
- 17 Oct 2014 New trial record